Leo J. Schultze Kool

Leo J. Schultze Kool

Auto-generated profile, based on publicly available information

Leo J. Schultze Kool

Department of Medical Imaging, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2018 in Acta Obstetricia et Gynecologica Scandinavica
Verified
Journal Article
Open access
PDF file
MSMiranda Steenbeek
Miranda Steenbeek
CVCarine J.M. van der Vleuten
Carine J.M. van der Vleuten
LKLeo J. Schultze Kool
Leo J. Schultze Kool
TNTheodoor E. Nieboer
Theodoor E. Nieboer
Introduction: In the work‐up of patients with suspected pelvic congestion syndrome, venography is currently the gold standard. Yet if non‐invasive diagnostic tools are found to be accurate, invasive venography might no longer be indicated as necessary.Material and methods: A literature search in Pubmed and EMBASE was performed from inception until 6 May 2017. Studies comparing non‐invasive diagnostic tools to a reference standard in the work‐up of patients with (suspected) pelvic congestion syndrome were included. Relevant data were extracted and methodological quality of individual included studies was assessed by the Quality Assessment of Diagnostic Accuracy Studies (QUADAS‐2) tool.Results: Nine studies matched our inclusion criteria. Six studies compared ultrasonography to venography and three studies described a magnetic resonance imaging technique. In using transvaginal ultrasonography, the occurrence of a vein greater than five mm crossing the uterine body had a specificity of 91% (95% CI; 77–98%) and occurrence of pelvic varicoceles a sensitivity and specificity of 100% (95% CI; 89–100%) and 83–100% (95% CI; 66–93%), respectively. In transabdominal ultrasonography, reversed caudal flow in the ovarian vein accounted for a sensitivity of 100% (95% CI; 84–100%). Detection of pelvic congestion syndrome with magnetic resonance imaging techniques resulted in a sensitivity varying from 88 to 100%.Conclusions: The sensitivity of ultrasonography and magnetic resonance imaging seem to be adequate, which indicates a role for both tests in an early stage of the diagnostic workup. However, due to methodological flaws and diversity in outcome parameters, more high standard research is necessary to establish a clear advice for clinical practice.

13 October 2020 in European Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
FBFrédérique C. M. Bouwman
Frédérique C. M. Bouwman
SKSilje S. Kooijman
Silje S. Kooijman
BVBas Verhoeven
Bas Verhoeven
LKLeo J. Schultze Kool
Leo J. Schultze Kool
CVCarine J. M. van der Vleuten
Carine J. M. van der Vleuten
IBIvo de Blaauw
Ivo de Blaauw
This retrospective study examines the outcomes of sclerotherapy in children with (veno)lymphatic malformations who received sclerotherapy between 2011 and 2016 (116 children, 234 procedures). Complication severity was classified using the Society of Interventional Radiology classification. Clinical response was rated on a scale of 0 (no change) to 3 (good improvement). The sclerosants used were bleomycin (n = 132; 56%), lauromacrogol (n = 42; 18%), doxycycline (n = 15; 6%), ethanol (n = 12; 5%), or a combination (n = 33; 14%). Four major and 25 minor complications occurred without significant differences between the agents. The median response rate per procedure was 2—some improvement—for all sclerosants. However, in pure LMs (67%), bleomycin and a combination of agents resulted in the best clinical response. On patient level, all had some or good clinical response. Mixed macrocystic and microcystic lesions showed a significantly lower clinical response (median 2 versus 3; p = 0.023 and p = 0.036, respectively) and required significantly more procedures (median 2 versus 1; p = 0.043 and p = 0.044, respectively) compared with lesions with one component.Conclusion: Sclerotherapy for (V)LMs in children is safe and effective. Bleomycin is the most frequently used agent in this clinic and seemed most effective for pure LMs. Mixed macrocystic and microcystic lesions are most difficult to treat effectively. What is Known:• A variety of agents can be used for sclerotherapy of lymphatic malformations in children.• Macrocystic lesions have favorable outcomes compared with microcystic and mixed lesions. What is New:• Bleomycin and a combination of agents seem to be most effective to treat lymphatic malformations in children.• Mixed macrocystic and microcystic lesions are more difficult to treat effectively compared with lesions with either one of these components.

13 July 2022 in European Journal of Neurology
Verified
Journal Article
Closed access
ADAnne Dompmartin
Anne Dompmartin
CVCarine J. M. van der Vleuten
Carine J. M. van der Vleuten
VDValérie Dekeuleneer
Valérie Dekeuleneer
TDThierry Duprez
Thierry Duprez
NRNicole Revencu
Nicole Revencu
LBLaurence Boon
Laurence Boon

8 May 2024 in Children
Verified
Journal Article
Open access
PDF file
FBFrédérique C. M. Bouwman
Frédérique C. M. Bouwman
BVBas Verhoeven
Bas Verhoeven
WKWillemijn M. Klein
Willemijn M. Klein
LKLeo J. Schultze Kool
Leo J. Schultze Kool
IBIvo de Blaauw
Ivo de Blaauw
Congenital vascular malformations (CVMs) are the result of an aberrant development during embryogenesis. Although these lesions are present at birth, they are not always visible yet. Once symptomatic, patients suffer from pain, bleeding, ulcers, infections or lymphatic leakage, depending on the subtype of vessels involved. Treatment includes conservative management, surgery, sclerotherapy, embolization and pharmacological therapy. The clinical presentation varies widely and treatment can be challenging due to the rarity of the disease and potential difficulties of treatment. This review gives an overview of the historical developments in diagnosis and classification and exposes the key elements of innovations in the past decades on the identification of genetic mutations and personalized treatment. These advances in the field and a multidisciplinary approach are highly valuable in the optimization of clinical care aimed at both curing or stabilizing the CVM and pursuing physical and psychosocial wellbeing.

4 September 2021 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
KGKarlijn H. J. Groenen
Karlijn H. J. Groenen
AJAnnika Jacobsen
Annika Jacobsen
MKMartijn G. Kersloot
Martijn G. Kersloot
BVBruna dos Santos Vieira
Bruna dos Santos Vieira
EEEsther Van Enckevort
Esther Van Enckevort
LKLeo Schultze Kool
Leo Schultze Kool
Background: Patient data registries that are FAIR—Findable, Accessible, Interoperable, and Reusable for humans and computers—facilitate research across multiple resources. This is particularly relevant to rare diseases, where data often are scarce and scattered. Specific research questions can be asked across FAIR rare disease registries and other FAIR resources without physically combining the data. Further, FAIR implies well-defined, transparent access conditions, which supports making sensitive data as open as possible and as closed as necessary. Results: We successfully developed and implemented a process of making a rare disease registry for vascular anomalies FAIR from its conception—de novo. Here, we describe the five phases of this process in detail: (i) pre-FAIRification, (ii) facilitating FAIRification, (iii) data collection, (iv) generating FAIR data in real-time, and (v) using FAIR data. This includes the creation of an electronic case report form and a semantic data model of the elements to be collected (in this case: the “Set of Common Data Elements for Rare Disease Registration” released by the European Commission), and the technical implementation of automatic, real-time data FAIRification in an Electronic Data Capture system. Further, we describe how we contribute to the four facets of FAIR, and how our FAIRification process can be reused by other registries. Conclusions: In conclusion, a detailed de novo FAIRification process of a registry for vascular anomalies is described. To a large extent, the process may be reused by other rare disease registries, and we envision this work to be a substantial contribution to an ecosystem of FAIR rare disease resources.

1 July 2009 in Netherlands Heart Journal
Verified
Journal Article
Open access
PDF file
LVL. B. J. van der Velden
L. B. J. van der Velden
LOL. C. Otterspoor
L. C. Otterspoor
LKL. J. Schultze Kool
L. J. Schultze Kool
GBG. J. Biessels
G. J. Biessels
FVFreek W.A. Verheugt
Freek W.A. Verheugt
An acute myocardial infarction is a rare complication of a subarachnoid haemorrhage. The combination of these two conditions imposes important treatment dilemmas. We describe two patients with this combination of life-threatening conditions. Patient 1 was treated with emergency percutaneous coronary intervention followed by clipping of the anterior communicating artery aneurysm. Six months after discharge the patient's memory and orientation had almost completely recovered. Patient 2 was treated with aspirin until coiling of the aneurysm could be performed. After successful coiling low-molecular-weight heparin was added. One week later the patient died due to a free wall rupture. (Neth Heart J 2009;17:284–7.)